Gabelli & Co Investment Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5M	Buy	+159,003	New	+$4.69M	0.73%	30

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gabelli & Co Investment Advisers's CPRX Position: Q2 2026 in Review

Gabelli & Co Investment Advisers opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 159,003 shares worth $5M. The stake represents 0.73% of the portfolio and ranks #30 among its holdings.

396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Gabelli & Co Investment Advisers held 159,003 shares of Catalyst Pharmaceutical worth $5M as of Q2 2026.
Catalyst Pharmaceutical was a new Gabelli & Co Investment Advisers position in Q2 2026.
Catalyst Pharmaceutical made up 0.73% of Gabelli & Co Investment Advisers's portfolio in Q2 2026, its #30 holding.
396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.